Genentech Enspryng cuts MOGAD relapse risk 68%
See more from StockTitan in Google Search and AI answers.
Adds StockTitan as…
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is…
Roche ENSPRYNG cuts MOGAD relapse risk 68%
Roche (OTCQX: RHHBY) reported Phase III METEOROID results showing ENSPRYNG (satralizumab) reduced risk…